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options, aiming at the induction of anti-tumor T cells responses,
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dicted in silico, nonecouldbevalidatedbymass spectrometry. Instead,
apersonalizedmulti-peptidevaccinecontainingnon-mutated tumor-
associated epitopes was designed and applied. Immunomonitoring
showed vaccine-induced T cell responses to three out of seven pep-
tides administered. The pulmonary metastasis resected after start of
vaccination showed strong immune cell infiltration and perforin pos-
itivity, in contrast to the previous lesions. The patient remains clini-
cally healthy, without any radiologically detectable tumors since
March 2013 and the vaccination is continued.
Conclusions: This remarkable clinical course encourages formal
clinical studies on adjuvant personalized peptide vaccination in
cholangiocarcinoma.
Lay Summary:Metastatic cholangiocarcinomas, cancers that
originate from the liver bile ducts, have very limited treatment
options and a fatal prognosis. We describe a novel therapeutic
approach in such a patient using a personalized multi-peptide
vaccine. This vaccine, developed based on the characterization
of the patient’s tumor, evoked detectable anti-tumor immune
responses, associating with long-term tumor-free survival.
 2016 European Association for the Study of the Liver. Published
by Elsevier B.V. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).16 vol. 65 j 849–855
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Introduction
Cholangiocarcinomas (CCA), heterogeneous malignant epithelial
tumors originating from hepatic ductal cells, are typically diag-
nosed in a late stage and have a particularly poor prognosis [1].
CCA are rare in theWestern world (0.5–1.5/100,000 persons), while
they are the second most frequent primary liver cancer worldwide
[2]. Risk factors include liver cirrhosis, viral hepatitis, hepatobiliary
flukes and primary sclerosing cholangitis [1]. A recent systematic
meta-analysis of 4,756 patients with intrahepatic cholangiocarci-
noma (iCCA) reported 5-year survival rates between 5 and 56%
and a median survival of 28 months [3]. Surgical resection of
tumors is so far the only effective therapeutic strategy and neither
adjuvant chemotherapy nor radiotherapy has shown any clear ben-
efit [3]. Prognosis of lymph node metastasis in iCCA is usually fatal
and the reported 5-year survival rates are 0–8% [4,5].
Novel treatment options using targeted agents off-label or loco-
regional therapies have only shown limited success in CCA [6].
Intra and inter tumor genetic heterogeneity among iCCA, evidenced
by whole exome sequencing (WES), calls for personalized therapies
[7]. An encouraging new immunotherapy, using adoptive transfer
of ex vivo expanded autologous CD4+ T cells targeting a mutated
antigen, yielded spectacular clinical results in a patient with non-
resected metastatic CCA [8]. This success, previously unheard of
in CCA, points towards the possible effectiveness of immunothera-
pies. Furthermore, multi-peptide vaccine-induced immune
responses correlate positively with increased survival in cancer
[9,10]. In line with such promising immunotherapeutic develop-
ments, we report our findings in a patient with metastatic iCCA,
treated with a personalized multi-peptide vaccination. Since initial
diagnosis and first tumor resection, the patient had tumor recur-
rences twice in the liver, as well as a lung metastasis, underlining
the aggressiveness of the disease. The vaccine was designed based
on WES, whole transcriptome sequencing (WTS) and HLA ligan-
dome analysis of the tumors and induced long-term functional vac-
cine specific T cells. Remarkably, the tumor did not metastasize
further and the patient is currently tumor-free, five years after ini-
tial diagnosis and 41 months after initiation of vaccination, sug-
gesting therapeutic effectiveness.Materials and methods
Next-generation-sequencing
As part of a research project (IndividuaLIVER, approved by the Institutional
Review Board at the University Hospital of Tübingen), WES of tumor and normal
tissue was performed for L06/10, L04/12 and P03/13 (Fig. 1). In addition, the tran-
scriptome of tumor tissue of L06/12 and P03/13 was sequenced. Further details
are provided in Supplementary Tables 6–8; and Supplementary Tables 11 and 14.
A total of four tumor samples (Formalin-Fixed, Paraffin Embedded tissue
(FFPE) shavings; L06/10; L03/11; L04/12; P03/13) and one reference sample
(blood) were sequenced with a custom cancer panel (SureSelect XT; Agilent,
Waldbronn, Germany) covering 1.566 Mbp of coding sequence (Supplementary
Table 3). On average a two-fold higher read count was generated for the tumor
samples compared to the reference sample (39,900,242 reads vs. 17,748,620
reads). This yielded a mean coverage depth of 1,065x for the tumor samples with
98% of regions of interest covered with at least 100x and 90% of the regions cov-
ered with at least 500x (For further details see Supplementary Tables 4 and 5).
The reference sample was sequenced to a mean coverage depth of 705x and a
98% 100x-coverage of the target region. Bioinformatic analysis for WES, WTS
and panel sequencing followed established in-house pipelines. Further details
including the bioinformatics analysis pipeline can be found in the Supplementary
materials and methods.850 Journal of Hepatology 201HLA typing
Two-digit HLA class I and II typing was performed by SSP-PCR at the Department
of Transfusion Medicine, University of Tübingen, following clinical routines. Typ-
ing at four-digit resolution using the WES data was performed by OptiType [11]
for HLA class I and further manual curation for HLA class II alleles, determining
the patient’s HLA allelotype to be: HLA-A⁄03:01/A⁄29:01, B⁄07:05/B⁄35:01,
C⁄04:01/C⁄15:05 and HLA-DRB1⁄01:01/DRB1⁄11:01/DRB3⁄02:02, DQB1⁄03:01/D
QB1⁄05:01. The results of OptiType are in accordance with the PCR-based two-
digit HLA typing.
Mass spectrometry
HLA ligands were immunoprecipitated from cryopreserved tumor tissues and
liver tissue (L03/10) as previously described [12] using the pan-HLA class I anti-
body, W6/32 (manufactured in-house). HLA ligands were purified using 3 kDa
cut-off centrifugal filters (Amicon, Maerck Millipore, Carrightwohill, Ireland),
desalted (C18 ZipTip; Merck Millipore, Darmstadt, Germany), concentrated (vac-
uum centrifuge; Bachofer, München, Germany) and analyzed by LC-MS/MS as
previously described [13]. Further details are provided in Supplementary materi-
als and methods and Supplementary Table 17. An individualized protein database
containing tumor-specific somatic mutations identified by WES/WTS was gener-
ated in FASTA format and used for spectral annotation using the Mascot search
engine (v2.2.0.4, Matrix Science, Boston, MA).
T cell in vitro immunomonitoring
The patient received 32 vaccinations in total between September 2012 and Febru-
ary 2016 (ongoing). EDTA-anticoagulated blood (45 ml) and serum (5.5 ml) was
drawn at two time points before vaccination and at regular intervals during the
course of vaccination. T cell responses to all vaccinated peptides (Table 1) were
monitored in peripheral blood mononuclear cells (PBMCs) isolated from blood
drawn before vaccination (either during the pre-vaccination screening (scr) or
at the first vaccination appointment (1V)) as well as during vaccinations 5V,
6V, 8V, 10V, 12V, 15V, 22V and 25V. PBMCs were pre-stimulated in vitro using
the vaccinated peptides and relevant negative control peptides and expanded
using IL-2 for 12 days (see details in Supplementary materials and methods)
[14,15]. Responses to HLA class I peptides were monitored by IFN-c ELISPOT
and HLA-peptide multimer staining, while responses to HLA class II peptides
and RGS-5 peptide were determined by IFN-c ELISPOT and ICS (for IFN-c, TNF-
b, IL-2 and IL-10) (all techniques are elaborated in Supplementary materials
and methods).
Histopathology
Tissue sections from paraffin embedded diagnostic tumor material obtained after
surgical resections (L06/10; L03/11; L04/12; P03/13) were assessed by a consul-
tant pathologist and FFPE shavings (>90% tumor fraction) used to isolate DNA
for panel sequencing (above) and IDH1 PCR. Further sections were used for addi-
tional immunohistochemical (IHC) analyses to complement CK7, Hep Par 1, Nap-
sin A and TTF1 stainings, which had already been assessed during routine
histopathology.
IHC staining was performed on an automated immunostainer, following the
manufacturer’s protocol (Benchmark, Ventana Medical Systems, Tucson, AZ).
Respective commercially available antibodies used, sources and dilutions are
summarized in Supplementary Table 1. Sections were assessed by a consultant
pathologist as negative (), positive with low (+), intermediate (++) and strong
(+++) staining in immunohistochemistry or by evaluating positive cells in 10 high
power fields counted and cell densities for the epithelial (E) and stromal (S) com-
partment respectively.
Results
Clinical course
A 56-year-old female patient, previously asymptomatic and
healthy without any established risk factors for primary liver can-
cers, was sonographically diagnosed with a big unilocular mass in
the right hepatic lobe (Ø 11.5 cm) in June 2010. Following atypi-
cal liver tri-segment resection (segments IVb, V, VI) and radical6 vol. 65 j 849–855
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Fig. 1. Clinical course and therapy. The course of the disease is subdivided in quarters of the year (Q) and the interventions performed (surgery/vaccination) are shown.
Clinical imaging results for relevant events are depicted exemplarily in chronological order. Further exemplary imaging results depicting the course of disease can be
accessed in Supplementary Figs. 1–15. The multi-peptide vaccination schedule is also indicated chronologically annotated for days (after initiation) and count of
vaccinations. Seg, segment; R-classification, R0: no residual tumor; R1: microscopic residual tumor; R2: macroscopic residual tumor; lhs/rhs, left/right hand side;
classification of malignant tumours (TNM Classification) (UICC): T = tumor extent (0–4); N = positive lymphnodes (0–1); M = Metastasis (0–1); L = lymphinvasion (0–1);
V = venous invasion (0–1); G = grading (1–3); p = histopathological staging; c = clinical staging; Ø diameter; s.c., subcutaneous; i.d., intradermal; nV = nth vaccination.
Table 1. Composition of the multi-peptide vaccine.
Samples analyzed L06/10 P03/12 L06/10
Ref. Tumor characterization
Peptide sequence Identifier Mass (Da) AA position HLA Epitope Transcript ID RNA (FPKM) MS 2
GLASFKSFLK RGS5 1096.6 74-83 A*03 [24] NM_003617 32 81 +
SLLTSSKGQLQK ADFP-2 1288.7 369-380 A*03 [13] NM_001122 525 53 +
TSALPIIQK ADFP-3 969.6 63-71 A*03 [13] NM_001122 525 53 +
SLFPNSPKWTSK MMP7-(1) 1390.7 79-90 A*03 [26] NM_002423 141 1113 -
NPPSMVAAGSVVAAV CCND1 1368.7 198-212 DR [25, 27] NM_053056 70 30 n.d.
HSKIIIIKKGHAKDSQ IGFBP3 1802.1 142-157 DR [27] NM_001013398 1 0 n.d.
SQDDIKGIQKLYGKRS MMP7-(2) 1835.0 153-168 DR [9, 27] NM_002423 141 1113 n.d.
Peptides are listed alongside their sequence, identifier of the core protein, molecular mass and position of the peptide in the respective corresponding source protein and
HLA-restrictions of the peptides. Characterization of the patient’s tumor, HLA ligandome analysis (LC-MS/MS) as well as whole transcriptome sequencing (WTS) of two
tumor manifestations (L06/10 – primary tumor; P03/13 lung metastasis) are shown with respective FPKM values (fragments per kilobase mapped) for the transcripts of
interest. AA (amino acid); RGS (regulator of G-protein signaling); ADFP (adipose differentiation-related protein/Perlipin); CCND (cyclin D); IGFBP (Insulin-like growth
factor-binding protein); MMP (matrix metalloproteinase); MS2 (tandem mass spectrometry); Ref. (References).
JOURNAL OF HEPATOLOGYsystemic lymphadenectomy, the tumor was staged as an incom-
pletely resected iCCA (pT1, pN1 (1/20), (pL0, pV0), cM0/R1)
(abbreviated as L06/10) (Fig. 1). Histological assessment indi-
cated a poorly differentiated (G3) monomorphic adenocarcinoma
with partially solid appearance, displaying moderate desmoplas-
tic stroma. The tumor cells, with extensive eosinophilic cyto-
plasm and hyperchromatic and moderately polymorphic nuclei,
were strongly positive for cytokeratin (CK) 7 and negative for
Hep Par 1 (Fig. 2B), supporting the diagnosis of iCCA [16]. Adja-
cent liver tissue showed no steatosis/fibrosis or any indication
of liver pathology. The disease recurred rapidly and two new
lesions required another atypical liver resection (segments III,
V, VI; R0) nine months later (L03/11) and a third one combinedJournal of Hepatology 201with a right hemi-hepatectomy (R1) 22 months after initial
diagnosis (L04/12) (Fig. 1). Both recurring liver lesions,
L03/11 and L04/12, were also analyzed by immunohistochem-
istry (Fig. 2B and Supplementary Table 2). At this stage, faced
with a fatal disease without any standard treatment options,
based on expert opinions and a positive individual medical
risk-benefit assessment, a multi-peptide vaccine was consid-
ered as a last resort (according to principle 35 Declaration of
Helsinki (Seoul 2008)). The patient had previously volunteered
to participate in a scientific research project (IndividuaLIVER)
aimed at the development of personalized tumor vaccines,
which enabled extensive molecular characterization of the
tumors.6 vol. 65 j 849–855 851
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Fig. 2. Tumor characterization. Characterization of the various surgically
resected tumors is shown. (A) Tumor location and putative ancestry based on
shared driver mutations are indicated with a color code. (B) Tumors were
assessed by immunohistochemistry and qualitative staining patterns ( negative;
+ slightly positive; ++ moderately positive; +++ strongly positive) are given for
different immune and tumor markers. Staining for Hep Par 1 and CK7 supported
the initial diagnosis of cholangiocarcinoma (L06/10) and staining of P03/13 for
thyroid transcription factor-1 (TTF1) and Napsin A ruled out a primary lung
adenocarcinoma. Further, counts for immune cell infiltrates in the epithelial
compartment are given for each tumor and microscopic pictures (100) of
perforin staining are shown. More detailed data is provided in Supplementary
Table 2.
Case ReportNext-generation sequencing and HLA ligandome analysis for the
identification of vaccine targets
First the tumor was analyzed to design a personalized anti-tumor
vaccine based on mutated HLA ligands. We generated compre-
hensive datasets through sequencing (including WES and WTS)
and screened for tumor-specific mutations (Supplementary
Tables 8, 11 and 14). Then, using mass spectrometry, we assessed
the natural HLA class I ligands on the tumor (HLA ligandome
analysis) (Supplementary Table 17). Although we predicted sev-
eral HLA ligands in silico containing mutations from the sequenc-
ing data, we were unable to find direct evidence for their
presence in the ligandome (see Supplementary Tables 8–17 for
detailed information, and Supplementary materials and methods
for experimental procedures). Instead, we found several non-
mutated HLA ligands that had been previously identified in other852 Journal of Hepatology 201tumor entities (Supplementary Table 17). Based on these obser-
vations we selected a multi-peptide vaccine composed of seven
tumor-associated epitopes (Table 1) containing four HLA-A⁄03
restricted short peptides and three promiscuous HLA-DR long
peptides. Three of the short peptides were confirmed as natural
HLA ligands on the patient’s tumor tissue by mass spectrometry
(L06/10) (Supplementary Figs. 16–21) and source protein tran-
scripts for all but one of the seven vaccine peptides were found
to be expressed by WTS (FPKM >25) in the tumor (Table 1 and
Supplementary Table 18). The final peptide selection was made
by combining the following two aspects, first, known epitopes
from our in-house database that had been applied in patients
previously, following an individual risk-benefit assessment were
considered. Secondly, those peptides were prioritized according
to evidence for their presence on the tumor tissue of the patient.
Vaccination, further clinical course and immunomonitoring
After comprehensive and detailed informed consent by multiple
attending physicians and a written approval by the patient,
immunization using the multi-peptide vaccine was initiated in
September 2012. The vaccine contained 300 lg per peptide in
300 ll of 33% DMSO (in H2O) emulsified in montanide ISA 51
VG ad 1 ml. It was applied subcutaneously (s.c.), according to a
tapering vaccination schedule, followed by topical application
of 250 mg imiquimod twice, with a 12 h interval (Fig. 1).
In March 2013, a suspect solitary pulmonary lesion (Ø 1.7 cm)
in the right middle lobe was identified in CT scans (abbreviated as
P03/13) and was found to be metabolically active in 18FDG-PET
(Fig. 1). At this point, re-inspection of the CT scans performed
in September 2012, prior to the start of the vaccination, revealed
a small lesion at the same location (Supplementary Figs. 10–13).
In an ensuing pleural middle lobe and sleeve resection of the pul-
monary artery with lymphadenectomy (N0 (0/9), R0), P03/13 was
removed. Histological and immunohistochemical analyses con-
firmed an iCCA metastasis and ruled out a primary pulmonary
malignancy (Fig. 2B).
Due to the absence of adverse events apart from expected
minor inflammatory reactions at the vaccination site [17] and
the lack of therapeutic alternatives, the peptide vaccination was
continued as stated above. After 18 s.c. vaccinations, application
mode was changed to intradermal (i.d.) (omitting montanide)
for further vaccinations (until February 2016). Latest radiological
imaging results (CT scan, February 2016), obtained 41 months
after initiation of the vaccination showed no evidence of tumor
recurrence, neither intra- nor extrahepatic.
In vitro T cell immunomonitoring showed a rapid (as early as
the 5th vaccination i.e., 5V) and persisting (detectable until the
last monitored time point- 25V) induction of T cells specific for
three vaccine peptides derived from regulator of G-protein signal-
ing 5 (RGS5), cyclin D1 (CCND1) and matrix metalloproteinase-7
(MMP7-(1)) (Fig. 3). T cell cytokine response was detected against
CCND1 by IFN-c ELISPOT (Fig. 3A) and was confirmed to be a CD4+
response by intracellular cytokine staining (ICS) (Fig. 3B left lower
panel). The RGS5 peptide elicited a CD4+ T cell response
(Fig. 3B, 3C). Indeed, binding of this short peptide to HLA class II
molecules was proven by mass spectrometry following immuno-
precipitation and its ability to elicit CD4 T cell responses was
observed in other patients (unpublished own data). Such observa-
tions are not uncommon and have been reported by others [18].
We also detected MMP7-(1) specific CD8+ T cells by HLA-6 vol. 65 j 849–855
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Fig. 3. Immunomonitoring of patient PBMCs for vaccine induced T cell responses. PBMCs were pre-stimulated using either peptide pool I (RGS-5, ADFP-2, ADFP-3,
MMP7-(1) and HIV-A03) or peptide pool II (CCND1, IGFBP3, MMP7-(2) and Filamin-A), and expanded for 12 days using IL-2. (A) 300,000 cells (Class I binding peptides) or
200,000 (for class II binding peptides) were re-stimulated in triplicates (duplicates for pre-vaccination ‘scr’ time point) in an IFN-c ELISPOT assay using individual peptides.
The top panel shows the normalized spot counts for individual peptide stimulations and the bottom panel shows examples of scanned ELISPOT wells. At least 700,000 cells
were re-stimulated with the respective peptides, in the presence of Brefeldin A and GolgiStop and 12 h later, intracellular IFN-c and TNF were stained and analysed for B
and C. (B) Exemplary dot plots of IFN-c and TNF production by CD4(+) cells in response to RGS5 and CCND1 peptides, collected at the 25th vaccination (25V) are shown in
the left panel. TNF production by CD8(+) cells in response to MMP7-(1) peptide are shown in the right panel (top). MMP7-(1) multimer staining of the corresponding
vaccination time point (13V) is shown in the right panel (bottom). (C) Frequencies of the RGS5 peptide induced cytokine(+) live CD4(+) lymphocytes are shown (left y axis:
IFN-c right y axis: TNF). (D) At least 600,000 cells were analyzed by HLA-peptide multimers (class I). MMP7-(1) multimer(+) cells within live CD4() lymphocytes are shown
and the % of multimer(+) CD8(+) lymphocytes are indicated.
JOURNAL OF HEPATOLOGYpeptide multimer staining (Fig. 3D), these cells did not pro-
duce any IFN-c but TNF upon peptide specific stimulation
(Fig. 3B).
Since IL-10 induction in serum has been reported to be
associated with prolonged imiquimod application in a mouse
model [19], we measured serum levels of IL-10 during the course
of vaccination. IL-10 levels remained below the lower limit
of quantification (LLoQ) using a Luminex based sandwich
immunoassay. Nevertheless, we were able to detect baseline
levels of IL-10 (1.46 to 4.55 pg/ml) using an in-house developed
and technically validated, ultrasensitive single molecule array
(SIMOA) immunoassay (unpublished) on the Quanterix platform
(Supplementary Table 20; Supplementary materials and
methods), coherent with data published for healthy subjects
[20,21].Journal of Hepatology 201In addition, detailed immunohistochemical analyses of tumor
tissue indicated that both CCND1 and MMP7 were indeed con-
stantly expressed in the excised tumors during the course of the dis-
ease (Fig. 2B). Strikingly, stromal T cell infiltration was more
pronounced in P03/13, resected six months after initiation of vacci-
nation, than in the earlier liver lesions, evidenced by CD3 staining
(Fig. 2B). Further, the cytotoxic molecule perforin, previously absent
in the liver tumors, was strongly positive in the pulmonary metasta-
sis, confirming the presence of activated cytotoxic T cells within the
tumor (Fig. 2B). Somatic mutations were detected in seven potential
tumor suppressor/oncogenes in a somatic cancer panel (Fig. 2A and
detailed in Supplementary Table 4). Among these seven mutations,
three (in IDH1, PBRM1 and KMT2C) were detected in all the four
tumors analyzed verifying the common cellular origin of all different
malignant lesions that occurred over time.6 vol. 65 j 849–855 853
Case Report
Discussion
Cancer immunotherapy has recently gained considerable
momentum given the clinical success of checkpoint inhibitors.
Particularly in metastatic iCCA, spectacular results have been
obtained using the adoptive transfer of mutation-specific CD4+
T cells in a patient [8]. Faced with a malignant disease with recur-
ring tumor, lymphatic metastasis, extremely poor prognosis and
no established standard therapies, we decided to explore experi-
mental therapeutic alternatives. Initially we intended to design a
personalized peptide vaccine targeting individual tumor muta-
tions presented by HLA class I molecules to induce tumor reactive
T cells [22,23]. However, based on WES (Supplementary Tables 8,
11 and 14) the in silico predicted mutated HLA ligands (Supple-
mentary Tables 9, 10, 12, 13, 15 and 16) could not be confirmed
as naturally presented HLA ligands by mass spectrometry (Sup-
plementary Table 17), indicating their low abundance or sub-
clonal presentation in the patient’s tumor samples. Our study in
leukemia patients identified non-mutated epitopes as valid tar-
gets of clinically relevant anti-cancer T cell responses, suggesting
that non-mutated ligands may indeed be tumor-specific due to
altered antigen presentation on tumor cells [13]. We therefore
pursued a personalized vaccination approach based on non-
mutated ligands presented by the patient’s tumor. Consequently,
we selected a vaccine containing seven tumor-associated pep-
tides (TUMAPs) that had been shown to be immunogenic in can-
cer patients and/or in vitro T cell assays [9,13,24–27], to secure a
positive individual risk-benefit ratio combined with best avail-
able evidence for target representation on the patient’s tumor
and immunogenicity. Of the four short peptides in the vaccine,
transcripts of their source proteins were expressed in the
patient’s tumors while three could additionally be confirmed as
natural HLA class I ligands by mass spectrometry (Table 1, Sup-
plementary Figs. 16–21, and Supplementary Tables 17 and 18).
We also included three promiscuous HLA-DR binding long pep-
tides in the vaccine to simultaneously induce CD4 help (Table 1).
The multi-peptide vaccination induced functional T cell
responses against 3 out of the 7 peptides (Fig. 3). Analysis of
the pulmonary metastasis (P03/13), which pre-existed in an
indiscernible stage prior to vaccination (Supplementary Figs. 10–
13) and was resected 6 months after the start of the vaccination,
showed a higher infiltration of CD3+ cells than the tumors
resected before the vaccination. P03/13 also displayed strong
expression of perforin (Fig. 2B), which was absent in all other
tumor lesions. Although the microenvironment in lung and liver
tissue may be fundamentally different and influence immune cell
recruitment, our data clearly suggests vaccination induced infil-
tration of anti-tumor T cells into the lung metastasis but cannot
provide absolute certainty.
Given the established genetic heterogeneity of iCCA [7], we
identified known driver mutations such as IDH1 [7], KMT2C [7]
and PBRM1 [28] and addressed the ancestry of the tumor lesions
(Fig. 2A). These findings enabled us to safely rule out any de novo
malignancy. The inherent individual tumor heterogeneity at the
level of malignant driver mutations suggests that metastasis
was a rather early event [7]. Although some of the mutations evi-
denced might activate targetable signaling pathways, no
approved targeted therapy was available for our patient much
less any evidence for effectiveness in the adjuvant setting.
To our knowledge this is the first report on a personalized
adjuvant peptide-based immunotherapy in iCCA. The remarkable854 Journal of Hepatology 201tumor-free status and the extended survival of the patient, extre-
mely rare in metastatic iCCA, make this a compelling case worth
reporting. The vaccine-induced T cell responses as well as the
increased T cell infiltration into the lung metastasis underline
the induction of anti-tumor immunosurveillance by the vaccine
and can be held responsible for the prevention of any further
metastasis and the current status of the patient. Based on our
results and previous reports of immunotherapy in CCA, we pro-
pose adjuvant personalized peptide-based immunotherapy in
iCCA as a highly promising new therapy well worth exploring
in formal clinical trials.Note added in proof
After this manuscript was resubmitted, the patient presented
with a new lesion in the liver, which then could be completely
resected. A thorough analysis of this tissue is being performed,
in particular with respect to characterizing the tumor immune
infiltrate and signs of tumor immune escape.Financial support
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